Abstract 6021
Background
Quality of life (QoL) has become an integral part of breast cancer (BC) management and been considered an important endpoint of clinical trials. Our objective was to report the results of the first Tunisian study assessing the QoL in BC and to identify the specific demographic characteristics.
Methods
One hundred and ten patients with BC from the department of Medical oncology of the Abderrahman Mami hospital were enrolled in the study in April, 2018. EORTC QLQ-BR23 (European Organization for Research and Treatment of Cancer) Questionnaire was used to assess specifically functional and symptoms scales/items of BC patients. Functional scales consisted of body image (BRBI), sexual functioning (BRSEF), enjoyment (BRSEE) and future perspective (BRFU). Symptom scales / items included systemic therapy side effects (BRST), breast (BRBS), arm (BRAS) symptoms and upset by hair loss (BRHL). A high score for a functional scale represents a healthy level of functioning and a high score for a symptom scale / item represents a high level of symptomatology.
Results
Median age was 52 years (range, 27-75 years) and 70.9% were above the age of 40. Fifty six of patients were menopausal and 19.1% had metastatic disease. Most of women were married (68.2 %), housekeepers (46.4%) and living in urban area (61.8%). Radical surgery was performed in 45.5% of cases and 59.1% of patients were receiving chemotherapy. We identified low scores of BRSEE (47.91, ± 31.44) and BRFU (51.81, ± 37.12) and high scores of BRBS (30.50, ±25.6) and BRAS (26.74 ±24.08) indicating a poorer QoL. Whereas, BRBI (74.33±26.07), BRSEF (77.42±27.79), BRST (40.6 ±20.16) and BRHL (38.46, ± 42.66) were not associated with poorer QoL. Marital status had significant positive effect on body image (Married women: 70.83 vs 70, p = 0.03), sexual functioning (98.14 vs 70.88, p = 0.011) and future perspective (60.80 vs 22.22, p = 0.00). Systemic therapy side effects were significantly higher among patients having chemotherapy (41.53 vs 32.53, p = 0.031). Arm symptoms were as well significantly more reported in patients aged above 40 (35.41 vs 26.78, p = 0.022) and menopausal (33.33 vs 24.80, p = 0.039).
Conclusions
Our study demonstrates the impact of demographic factors in QoL, which need to be systematically assessed by clinicians in breast cancer care.
Clinical trial identification
Legal entity responsible for the study
Soumaya Labidi.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract